Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Relapsing Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03560739
What this trial is testing

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 284
Early research (Phase 1)Ended earlyNCT01318421
What this trial is testing

ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 12
Not applicableEnded earlyNCT02266121
What this trial is testing

Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple SclerosisSecondary-progressive Multiple SclerosisCognitive Deficits+1 more
University Hospital of Mont-Godinne 100
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Testing effectiveness (Phase 2)Study completedNCT02988401
What this trial is testing

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Johns Hopkins University 105
Not applicableStudy completedNCT00704834
What this trial is testing

Gene Expression Profiles in Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
University of California, Davis 46
Not applicableUnknownNCT03787446
What this trial is testing

PET Study in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University of British Columbia 9
Testing effectiveness (Phase 2)Study completedNCT01448252
What this trial is testing

T Cell Vaccination in Patients With Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Hadassah Medical Organization 30
Early research (Phase 1)Study completedNCT02601885
What this trial is testing

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AbbVie 20
Not applicableNot Yet RecruitingNCT07631923
What this trial is testing

Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Primary Progressive+1 more
Shirley Ryan AbilityLab 35
Early research (Phase 1)Active Not RecruitingNCT06220201
What this trial is testing

Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Who this might be right for
Multiple SclerosisMyasthenia Gravis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 120
Early research (Phase 1)UnknownNCT02903537
What this trial is testing

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Fundació Institut Germans Trias i Pujol 16
Testing effectiveness (Phase 2)Study completedNCT02087631
What this trial is testing

Safety and Tolerability of Quetiapine in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University of Calgary 14
Large-scale testing (Phase 3)Study completedNCT04353492
What this trial is testing

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 562
Not applicableActive Not RecruitingNCT07235644
What this trial is testing

Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis

Who this might be right for
MS (Multiple Sclerosis)Multiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (Relapsing Remitting)
Uppsala University 184
Not applicableStudy completedNCT01080014
What this trial is testing

Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 252
Early research (Phase 1)Study completedNCT00103974
What this trial is testing

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Bayhill Therapeutics 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07804004
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

Who this might be right for
Progressive Multiple Sclerosis (PMS)Neuromyelitis OpticaMyelin Oligodendrocyte Glycoprotein Antibody-associated Disease+2 more
CRISPR Therapeutics 220
Not applicableStudy completedNCT07264725
What this trial is testing

Libyan Multiple Sclerosis Registry Study

Who this might be right for
Multiple Sclerosis
University of Zintan 369
Post-approval studies (Phase 4)Looking for participantsNCT07609719
What this trial is testing

Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Who this might be right for
Multiple Sclerosis
Genentech, Inc. 100
Next Page